Literature DB >> 7544340

Leukocyte adhesion induced by inhibition of nitric oxide production in skeletal muscle.

T Akimitsu1, D C Gute, R J Korthuis.   

Abstract

Superfusion of rat cremaster muscles with the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) elicited significant leukocyte adhesion to postcapillary venules (20- to 30-microns diameter), an effect that was attenuated by pretreatment with L-arginine (an NO precursor) or sodium nitroprusside (SNP) (an exogenous source of NO). In contrast to the effects of pretreatment, addition of SNP or L-arginine to the superfusate 30 min after the initiation of NO synthase inhibition failed to reverse the L-NAME-induced leukocyte adherence. However, this effect was reversed by administration of an anti-CD18 monoclonal antibody or 8-bromoguanosine 3',5'-cyclic monophosphate 30 min after L-NAME superfusion was initiated. These findings indicate that L-NAME promotes leukocyte adhesion to venular endothelium by a CD18-dependent mechanism in skeletal muscle and suggest that the failure of L-arginine or SNP to reverse L-NAME-induced leukocyte adherence is not due to a defect in signaling events that occur subsequent to activation of guanylate cyclase by NO derived from these agents. Because the simultaneous administration of superoxide dismutase (scavenges superoxide radicals) and SNP or L-arginine, but not superoxide dismutase alone, decreased L-NAME-induced leukocyte adherence, our results suggest that leukocyte adhesion caused by NO synthase inhibition may result in the generation of superoxide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544340     DOI: 10.1152/jappl.1995.78.5.1725

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  9 in total

1.  Temporal correlation between maximum tetanic force and cell death in postischemic rat skeletal muscle.

Authors:  H Suzuki; D C Poole; B W Zweifach; G W Schmid-Schönbein
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

2.  [Fractures of the extremities with severe open soft tissue damage. Initial management and reconstructive treatment strategies].

Authors:  P Schwabe; N P Haas; K D Schaser
Journal:  Unfallchirurg       Date:  2010-08       Impact factor: 1.000

Review 3.  Inflammatory responses to ischemia and reperfusion in skeletal muscle.

Authors:  D C Gute; T Ishida; K Yarimizu; R J Korthuis
Journal:  Mol Cell Biochem       Date:  1998-02       Impact factor: 3.396

4.  Nitric oxide regulates neutrophil migration through microparticle formation.

Authors:  Sarah Nolan; Rachel Dixon; Keith Norman; Paul Hellewell; Victoria Ridger
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

5.  Expression of a muscle-specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice.

Authors:  Hal X Nguyen; James G Tidball
Journal:  J Physiol       Date:  2003-05-23       Impact factor: 5.182

6.  Attenuation of changes in capillary fine structure and leukocyte adhesion improves muscle performance following chronic ischaemia in rats.

Authors:  O Hudlická; A Garnham; R Shiner; S Egginton
Journal:  J Physiol       Date:  2008-08-28       Impact factor: 5.182

7.  Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature.

Authors:  Mokarram Hossain; Syed M Qadri; Lixin Liu
Journal:  J Inflamm (Lond)       Date:  2012-07-19       Impact factor: 4.981

8.  Long-term Low-Intensity Endurance Exercise along with Blood-Flow Restriction Improves Muscle Mass and Neuromuscular Junction Compartments in Old Rats.

Authors:  Mohammad-Ali Bahreini Pour; Siyavash Joukar; Fariborz Hovanloo; Hamid Najafipour
Journal:  Iran J Med Sci       Date:  2017-11

9.  Nitric oxide and TNFα are critical regulators of reversible lymph node vascular remodeling and adaptive immune response.

Authors:  Stephanie L Sellers; Akiko Iwasaki; Geoffrey W Payne
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.